August 30, 2024 01:49 PM EDT
Pharma
FDA+

Ipsen sells pri­or­i­ty re­view vouch­er for high­est price since 2016

Zachary Brennan

Senior Editor

Ipsen Phar­ma­ceu­ti­cals sold its pri­or­i­ty re­view vouch­er to an uniden­ti­fied “large glob­al phar­ma­ceu­ti­cal com­pa­ny” for $158 mil­lion, it said this week, the high­est pub­licly an­nounced …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

SEC probe of Il­lu­mi­na’s Grail deal tar­gets sales fore­casts, sources say

Ex­clu­sive: A male con­tra­cep­tive may pre­vent 99% of preg­nan­cies. Now it’s up to a small biotech to fin­ish test­ing it

House pass­es Biose­cure Act, send­ing Chi­nese biotech ban to Sen­ate

GSK, iTeos re­ju­ve­nate strug­gling TIG­IT space with pos­i­tive Phase 2 Jem­per­li com­bo da­ta in lung can­cer

Ad­comm says In­ter­cep­t's rare liv­er dis­ease drug should not get full ap­proval

#ES­MO24 roundup: New da­ta on Am­gen’s PRMT5 in­hibitor seem lack­lus­ter, and Jazz’s HER2 an­ti­body

A service from the Financial Times